logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Syros Pharmaceuticals, Inc.


USPTO Granted Patents = 24



Trademarks = 2

Forward Citations = 59

Loading Chart...
Loading Chart...

53 inventors (with patents filed for the assignee):

goldMedal Jason J Marineau (16 out of 20 patents)

silverMedal Stephane Ciblat (15 out of 33 patents)

bronzeMedal Kevin Sprott (11 out of 21 patents)

4.  Anzhelika Kabro (10 out of 12 patents)

5.  Matthew Lucas Eaton (7 out of 7 patents)

6.  Darby Schmidt (7 out of 18 patents)

7.  Michael Bradley (7 out of 13 patents)

8.  Michael Robert McKeown (7 out of 12 patents)

9.  Melissa Leblanc (6 out of 9 patents)

10.  Serge Leger (6 out of 6 patents)

11.  Stephanie Roy (6 out of 8 patents)

12.  Dana K Winter (6 out of 8 patents)

13.  Tom Miller (6 out of 8 patents)

14.  Yi Zhang (5 out of 25 patents)

15.  M Arshad Siddiqui (5 out of 46 patents)


24 patents:

1. 12240869 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2025-03-04),
2. 11918592 - Inhibitors of cyclin dependent kinase 7 (CDK7) (2024-03-05),
3. 11753418 - Compounds for the modulation of Myc activity (2023-09-12),
4. 11447831 - Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists (2022-09-20),
5. 11311542 - Inhibitors of cyclin dependent kinase 7 (CDK7) (2022-04-26),
6. 11274103 - Compounds for the modulation of MYC activity (2022-03-15),
7. 11124527 - Compounds for the modulation of Myc activity (2021-09-21),
8. 11083728 - Compositions of cyclin dependent kinase 7 (CDK7) inhibitor (2021-08-10),
9. 11053552 - Methods of stratifying patients for treatment with retinoic acid receptor-α agonists (2021-07-06),
10. 11040981 - Pyrrolotriazine compounds and methods of inhibiting TAM kinases (2021-06-22),
11. 11040957 - Heteroaromatic compounds useful for the treatment of proliferative diseases (2021-06-22),
12. 10865206 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2020-12-15),
13. 10787444 - Compounds for the modulation of myc activity (2020-09-29),
14. 10738067 - Inhibitors of cyclin-dependent kinase 7 (CDK7) (2020-08-11),
15. 10697025 - Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists (2020-06-30),
Syros Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on discovering and developing medicines to control the expression of genes. The company's proprietary gene control platform enables the identification of therapeutic targets and the development of drugs to treat a range of diseases. By understanding the regulatory regions of the genome, Syros aims to create breakthrough treatments for cancer and other genetic diseases.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
24 Patents

#95 in Cambridge, MA

#800 in Massachusetts

#13,428 in US

#25,864 in the World

...
Cambridge, MA, United States of America

Syros Pharmaceuticals, Inc.

Forward Citations = 59

53 inventors:

goldMedal Jason J Marineau (16 out of 20 patents)

silverMedal Stephane Ciblat (15 out of 33 patents)

bronzeMedal Kevin Sprott (11 out of 21 patents)

4.  Anzhelika Kabro (10 out of 12 patents)

5.  Matthew Lucas Eaton (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…